← Scroll Down

News & Media

Diplomat Announces 2nd Quarter Financial Results

Diplomat to Release Second-Quarter 2018 Operating Results, Host Conference Call on Aug. 6

Diplomat Grants CEO Brian Griffin Inducement Awards Pursuant To NYSE Rule 303A.08

Diplomat Pharmacy Appoints Brian Griffin as Chief Executive Officer and Chairman of the Board

Diplomat Pharmacy in Final Stages of CEO Search Process

Diplomat Announces Strong 1st Quarter Financial Results

Diplomat to Participate in 43rd Annual Deutsche Bank Health Care Conference

Diplomat Launches CastiaRx, Industry-Leading Specialty Benefit Manager

The nation’s largest independent provider of specialty pharmacy services unites benefit-management companies to form specialty-focused CastiaRx.

Diplomat to Release Q1 2018 Operating Results, Host Conference Call on May 7

Diplomat to Present at 2018 Needham & Company Healthcare Conference

Diplomat to Present at 2018 Barclays Global Healthcare Conference

Diplomat Announces 4th Quarter and 2017 Year End Financial Results; Provides 2018 Guidance

Diplomat Managing Rising Drug Costs to Support Patients

The nation’s largest independent provider of specialty pharmacy services outlines initiatives to control rising drug costs

Diplomat to Release Fourth Quarter and 2017 Year End Financial Results, Provide 2018 Guidance and Host Conference Call On Monday, February 26, 2018

ThriveRx Wins ASPEN Clinical Nutrition Team of Distinction Award

ThriveRx, a division of Diplomat Specialty Infusion Group, has been recognized since 2013 for excellence in interdisciplinary clinical nutrition practice.

Diplomat Dispensing Advanced Kidney Treatment, CABOMETYX®

The nation’s largest independent specialty pharmacy is dispensing CABOMETYX® (cabozantinib) tablets, now with an expanded indication to include first-line therapy for patients with advanced renal cell carcinoma.

Diplomat Reaffirms 2017 Guidance, Provides Preliminary 2018 Outlook

The nation’s largest independent provider of specialty pharmacy services announces reaffirmed guidance for 2017 and preliminary 2018 projections.

Diplomat Initiates CEO Transition; Reaffirms 2017 Guidance and Provides Preliminary 2018 Outlook

Chain Drug Review: “Diplomat Works to Control Specialty Drug Costs”

Biosimilars, generic drugs and affordable branded drugs are top-of-mind at Diplomat Pharmacy Inc. this year as the specialty pharmacy looks to help health plans and patients rein in costs.

Pharmacy Practice News: “Best First Steps to Stem Pharmaceutical Waste”

Gary Rice, executive vice president of operations, discusses what Diplomat is doing to proactively minimize drug waste.

Diplomat is the nation’s largest independent provider of specialty pharmacy services—helping people with complex health conditions in all 50 states. Rooted in this patient care expertise, Diplomat also provides industry-focused specialty solutions through two brands: CastiaRx, which serves payers as the leading specialty benefit manager, and EnvoyHealth, which offers tailored solutions for healthcare innovators.

WHAT IS A SPECIALTY PHARMACY?

Specialty pharmacies provide treatment and intensive support for people with serious—and often chronic—health conditions. These pharmacies are equipped to handle medications with complex requirements around authorization, handling, administration, and more.

Mission

At Diplomat, we blend clinical excellence with a personal touch—for happier lives and health that lasts.

Philosophy

“Take good care of patients and the rest falls into place.” —Dale Hagerman, Diplomat cofounder

Accreditations

Diplomat is accredited by several third-party agencies committed to best practices in the industry. Accreditations include ACHC, ASHP, CPPA, URAC, VAWD, and VIPPS.

Downloads

Contact

press@diplomat.is

Connect with us